Use this URL to cite or link to this record in EThOS: http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.572203
Title: The significance of the EGFR pathway in malignant pleural mesothelioma
Author: Agarwal, Vijay
Awarding Body: University of Hull
Current Institution: University of Hull
Date of Award: 2012
Availability of Full Text:
Access from EThOS:
Access from Institution:
Abstract:
Introduction EGFR, MTOR and COX2 are up regulated in malignant pleural mesothelioma (MPM). In this study we aimed to determine the expression of Lipoxygenase enzymes (LOX), absence of PTEN protein expression and the cytotoxic effect of EGFR, MTOR and COX2 inhibitors in MPM. Materials and Methods Immunohistochemical analysis was performed in 93 archival MPM tissue samples to determine the expression of 5-LOX and 12-LOX and PTEN protein. The COX-2 positive cell lines MSTO-211H, NCI-H2052, NCI-H2452 (mesothelioma) and A549 (lung cancer) were utilised. All cell lines were tested for EGFR, KRAS and BRAF mutations. Cells were incubated with Cetuximab, Gefitinib, Rapamycin, Ku0063794 (MTOR kinase inhibitor) and Celecoxib as single agents and in combinations and analysed using the MTS assay. Results Positive 5-LOX expression was seen in 73% and positive 12-LOX expression was seen in 83% of MPM samples. PTEN protein expression was absent in 27% of the samples. A549 cells had a KRAS missense mutation at codon 12. No other EGFR, KRAS and BRAF mutations were identified in any of the cell lines. Cetuximab showed 50% cell growth inhibition in MSTO-211H cells at a concentration of 1.6 μM. All other cell lines were resistant to Cetuximab. All cell lines were resistant to Gefitinib. Rapamycin and Ku0063794 demonstrated 50% cell growth inhibition in NCI-H2052, NCI-H2452 and A549. Celecoxib demonstrated 50% cell growth inhibition in all cell lines. Cetuximab and Gefitinib were combined in turn with Rapamycin, Ku0063794 and Celecoxib. Cetuximab when combined with Celecoxib (NCI-H2052, NCI-H2452 and A549 cells) and Ku0063794 (MSTO-211H cells) demonstrated significant growth inhibition. Conclusions Our study suggests that 5LOX and 12LOX are expressed in the majority and PTEN protein expression is absent is a significant proportion of MPM tissue samples. Inhibition of MTOR pathway may be an important therapeutic strategy in patients with MPM.
Supervisor: Lind, Michael; Cawkwell, Lynn Sponsor: Hull York Medical School ; Scarborough & North-East Yorkshire Health Care NHS Trust ; Peel Foundation
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.572203  DOI: Not available
Keywords: Medicine
Share: